Foresight Diagnostic & Allogene Therapeutics Extend Collaboration to Develop Minimal Residual Disease (MRD) Assay

Shots:

• Foresight & Allogene have expanded their strategic collaboration to develop minimal residual disease (MRD) assay as companion diagnostic to identify candidates for Allogene’s ALPHA3 trial assessing cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL) pts
• As per the collaboration, Allogene & Foresight will develop Foresight’s MRD assay in the EU, UK, Canada & Australia to support cema-cel’s clinical development. Collaboration incl. investment for further MRD assay development, clinical sample testing & milestone payments
• Cema-cel is being evaluated in pivotal ALPHA3 trial as a 1L treatment for LBCL, where MRD+ pts in remission identified via Foresight’s CLARITY IUO assay may receive single cema-cel dose to prevent disease recurrence

Ref: Foresight Diagnostic | Image: Foresight Diagnostic & Allogene Therapeutics

Related News:- Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com